12:13:47 EST Mon 24 Feb 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 28,038,831
Close 2019-06-27 C$ 0.44
Recent Sedar Documents

Trillium shareholders elect eight to board

2019-07-02 09:00 ET - News Release

Mr. James Parsons reports

TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Trillium Therapeutics Inc. has provided the voting results from its annual and special meeting of shareholders held on June 27, 2019. The results of the director elections were as displayed in the table.


                                          % votes in      Votes  % votes 
Name                      Votes in favour     favour   withheld withheld 

Luke Beshar                     5,579,317         85    977,217       15 
Dr. Robert Kirkman              5,614,544         85    941,990       15 
Dr. Michael Moore               5,586,552         85    969,982       15 
Dr. Thomas Reynolds             5,580,252         85    976,282       15 
Dr. Robert Uger                 5,615,550         86    940,984       14 
Dr. Calvin Stiller              5,581,832         85    974,702       15 
Dr. Helen Tayton-Martin         5,687,094         87    869,440       13 
                                                                    

The shareholders of the corporation also voted to reappoint Ernst & Young LLP, chartered professional accountants, licensed public accountants as auditors of the corporation for the ensuing year. In addition, the shareholders approved the special resolutions to continue the corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act and the potential consolidation of the corporation's issued and outstanding common shares.

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.

© 2020 Canjex Publishing Ltd. All rights reserved.